Evolution of cancer cell lines draws concern

August 9, 2018, Harvard University
Long thought to be genetically stable and identical, cancer cell lines harbor significant levels of genetic variation, which may help explain why it can be hard to reproduce findings in cell line-based research. Credit: Susanna M. Hamilton and Lauren Solomon/Broad Communications

Cell lines form the backbone of cancer research. These individual groups of cells, typically collected from patients' tumor samples and cultured to grow indefinitely in the laboratory, enable everything from basic genetic research to drug discovery.

But while scientists have thought that individual remain genetically uniform even as they continue to grow and divide, they can in fact evolve in ways that dramatically change their responses to drugs, say researchers from the Broad Institute and collaborating institutions. This continuing evolution of within cell lines—potentially driven by the laboratory conditions in which they are grown—may help explain why different studies that use the same cell lines often have conflicting results.

These findings, reported in Nature, suggest that scientists need to take extra care to ensure that cell line-based models of accurately reflect the tumor they are studying. The research team has released an online tool, Cell STRAINER, to help scientists benchmark their models.

"The main message here is not that cell lines and culture-based models are bad. Rather, you should know your model, and understand its properties and limitations," said Broad founding core member and Cancer Program director Todd Golub, who was the study's co-senior author, along with Broad associate member and Dana-Farber Cancer Institute (DFCI) adult neuro-oncologist Rameen Beroukhim. "Knowing requires a level of genetic and genomic characterization beyond what we usually think about. Skipping this sort of careful characterization is not an option."

Evolution in a lab dish

Researchers have long recognized that cell lines do not perfectly mimic their tumors of origin. Still, they are considered representative and stable enough to provide accurate insights into cancer biology and drug response. In fact, every cancer treatment available today was at some point tested in these laboratory models.

However, scientists often struggle to reproduce study results from cell lines. In addition, no one has yet undertaken a systematic effort to measure how and the extent to which the cells in cancer cell lines change genetically over time, and whether those changes affect drug responses.

"You can find many examples in the literature pointing out inconsistencies in data from cell-line experiments," said Uri Ben-David, the study's first author and a postdoctoral fellow in the Golub lab. "We wanted to look for signs of evolution and connect the dots between changes within lines and those inconsistencies."

The researchers first began to suspect that these cell lines evolve when they reanalyzed sequencing data from 106 lines housed in two large collections: the Broad-Novartis Cancer Cell Line Encyclopedia (CCLE) and the Sanger Institute's Genomics of Drug Sensitivity in Cancer. These lines should be genetically identical in both collections, but the team found high levels of variability. For instance, 19 percent of the genetic mutations the team found were present in only one collection or the other.

The team then ran deep molecular analyses on 27 and 23 strains, respectively, of two widely used cell lines: the estrogen receptor-positive breast cancer line MCF-7, and the lung cancer line A549. The analysis included whole-genome DNA sequencing, targeted DNA sequencing of nearly 450 genes commonly mutated in cancer, and bulk and single-cell RNA sequencing. Each of the strains represented a batch of cells from the line with a distinct history (e.g., different kinds of lab manipulation, different length of time in culture, different original source).

Their data revealed striking genomic differences between strains, ranging from single base pair mutations to large-scale changes in genome structure (e.g., losses of entire chromosome arms) to major changes in gene expression—all indicating that the cell lines were neither as stable nor as identical as researchers thought. These genetic and expression differences also affected the strains' growth rates, cell size and shape, and other traits.

The team extended their findings by carrying out targeted sequencing on an additional 11 cancer cells lines representing a variety of tumor types (e.g., prostate, colon, liver, skin). Across the board, the team found extensive genetic variability within lines.

What drives these changes? By conducting experiments with different laboratory conditions, the team found that even changing the kind of nutrient media in which a cell line is cultivated can give some cells within a strain a growth advantage over others, allowing genetically distinct populations to evolve. And by extracting single cells and growing them in culture, the team also found that the progeny of isolated single cells could spontaneously acquire new mutations—showing that new, genetically diverse populations of cells could arise within a strain from individually isolated cells.

Strain variation affects drug sensitivity

To understand how these genetic changes might affect drug response, the team tested the 27 MCF-7 strains against 321 drugs. Indeed, any given drug's ability to slow the growth of or kill a strain's cells correlated with the strain's genetic features and its expression of genes targeted by the drug.

The findings complement those of another study led by Ben-David, Beroukhim, and Golub that examined patient-derived xenograft (PDX) models, which are generated by implanting tumor cells from a cancer patient into a mouse. In 2017, they reported in Nature Genetics that over time human cancer cells in PDX models lost characteristic genetic features seen in patients and gained new features not encountered in humans, changes that correlated with shifts in the models' drug sensitivities.

A change in perspective, and an opportunity

Taken together, the findings highlight a need for scientists to understand how the cells they are using may have diverged genetically from their parent line, so as to make accurate comparisons across experiments.

To that end, the study team has developed and will release an online tool, Cell STRAINER, to help researchers estimate how much a cell line strain they use has diverged genetically from reference samples in the Cancer Cell Line Encyclopedia collection.

The team also notes that the cell lines' capacity for evolution could actually provide an opportunity to study a variety of aspects of cancer biology and tumor evolution.

"Because the strains have the same general genetic background, you could test the same compound on two strains and use their features to study the compound's mechanism of action, or the influences of gene expression differences on sensitivity," said Golub, who is also the Charles A. Dana Investigator in Human Cancer Genetics at DFCI. "Or you could investigate tumor heterogeneity and the selective pressures that cause strains to evolve."

Explore further: A 'big data' approach to developing cancer drugs

More information: Uri Ben-David et al. Genetic and transcriptional evolution alters cancer cell line drug response, Nature (2018). DOI: 10.1038/s41586-018-0409-3

Related Stories

A 'big data' approach to developing cancer drugs

July 7, 2016
Scientists are starting to accumulate huge datasets on which genes mutate during cancer, allowing for a more systematic approach to "precision medicine." In a study publishing July 7 in Cell, researchers compared genetic ...

Editing false positives from cancer dependency maps drawn with CRISPR

October 31, 2017
The Broad Cancer Dependency Map team adds CRISPR-based data from 342 cancer cell lines to their growing catalog of genetic dependencies in cancer, and a new method for ensuring that data's accuracy.

Team develops technology to find optimum drug target for cancer

December 18, 2017
A KAIST research team led by Professor Kwang-Hyun Cho of the Department of Bio and Brain Engineering developed technology to find the optimum drug targets for specific types of cancer cells. The team used systems biology ...

Genetic signatures of gastric cancer cell lines reveal disease subtypes

April 30, 2015
Distinct subtypes of gastric cancer respond differently to drug treatments according to a study by A*STAR researchers. The finding could help optimize treatment for individuals with gastric cancer and improve their prognosis.

Pancreatic cancer resists personalized medicine—what researchers are doing to fight back

August 4, 2016
A team led by University of Arizona researchers is taking a new, patient-directed approach to treating pancreatic cancer. Rather than relying on conventional cell lines that have defined effective drug targets for other types ...

First volume of the Cancer Cell Line Encyclopedia made public

March 28, 2012
The goal of cancer treatment is to match the right drug to the right target in the right patient. But before such "personalized" drugs can be developed, more knowledge is needed about specific genomic alterations in cancers ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.